Jeffrey Basile, MD
Gastroenterology · Charleston, SCNPI 1437393964
Payments from drug & device makers
Across 231 payments — averaging $22.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$346
- Janssen Scientific Affairs, LLC$344
- Johnson & Johnson$328
- Takeda Pharmaceuticals U.S.A., Inc.$246
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$234
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,11399%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 90 | $1,915 |
| Pfizer | 10 | $346 |
| Janssen Scientific Affairs, LLC | 3 | $344 |
| Johnson & Johnson | 19 | $328 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $246 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $234 |
| Ardelyx, Inc. | 12 | $227 |
| Phathom Pharmaceuticals, Inc. | 8 | $165 |
| Celltrion USA Inc. | 11 | $162 |
| Sandoz | 8 | $127 |
| Medical Device Business Services, Inc. | 1 | $124 |
| Madrigal Pharmaceuticals | 5 | $117 |
| Ironwood Pharmaceuticals, Inc | 6 | $107 |
| Regeneron Healthcare Solutions, Inc. | 4 | $104 |
| Intercept Pharmaceuticals, Inc. | 5 | $85 |
| Sanofi | 2 | $66 |
| Bristol Myers Squibb | 3 | $58 |
| Lilly USA, LLC | 3 | $53 |
| Ipsen Biopharmaceuticals, Inc | 2 | $53 |
| Ambu Inc. | 1 | $48 |
| QOL Medical, LLC | 2 | $48 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Merck | 2 | $31 |
| Fresenius Kabi USA, LLC | 1 | $30 |
| Mirum Pharmaceuticals, Inc. | 1 | $23 |
| Braintree Laboratories, Inc. | 1 | $19 |
| Evoke Pharma, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Shionogi Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELARA$483
- XELJANZ$226
- Tremfya$139
- LINX Reflux Management System$124
How this compares
$5,143 in reported general payments places this provider in the 60th percentile of 259 gastroenterology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 35 | $995,047 |
| Humira(Cf) PenAdalimumab | 16 | $233,751 |
| LinzessLinaclotide | 149 | $164,132 |
| Humira PenAdalimumab | 23 | $153,984 |
| XifaxanRifaximin | 22 | $59,354 |
| CreonLipase/Protease/Amylase | 21 | $56,764 |
| TrulancePlecanatide | 35 | $33,768 |
| Mesalamine | 41 | $22,284 |
| Omeprazole | 973 | $19,526 |
| Colestipol Hcl | 81 | $10,750 |
| Dexlansoprazole DrDexlansoprazole | 34 | $7,790 |
| Famotidine | 384 | $6,908 |
| MotegrityPrucalopride Succinate | 12 | $6,263 |
| Sucralfate | 93 | $6,021 |
| NexiumEsomeprazole Magnesium | 13 | $4,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $328 | $995,04735 claims |
| AbbVieLinzess, Creon | $1,915 | $220,895170 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $234 | $93,12257 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $246 | $6,26312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 259 gastroenterology providers in South Carolina.
Other gastroenterology in Charleston
- Erin ForsterCharleston$2M
- Mark DeleggeCharleston$578K
- Brenda HoffmanCharleston$433K
- Theodore GourdinCharleston$369K
- Darin DufaultCharleston$321K
- Nathan ShoresCharleston$217K
- Alejandro SuarezCharleston$210K
- Peter CottonCharleston$193K
- David KochCharleston$48K
- Derek FeussnerCharleston$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.